Calibre Scientific has acquired DCS, a German supplier of immunohistochemistry reagents and equipment, with the specific focus on clinical pathology and oncology.
The acquisition will strengthen Calibre’s product and service portfolio across Germany, Austria and Switzerland.
After its founding in 1992, DCS has established a significant market presence in the immunohistochemistry space, supplying a comprehensive portfolio of primary antibodies, secondary reagents, as well as detection and automation systems.
CEO of Calibre Scientific, Ben Travis, said: “DCS has been serving the DACH market for over 30 years, entrenching itself in the supply chain ecosystem of both suppliers and customers alike. We have been thoroughly impressed with the Company’s technical expertise, knowledge of the market and quality product portfolio — so we look forward to further enhancing the value proposition DCS currently brings to the DACH region.”
“I’m very excited about the next chapter in DCS’ evolution, now as part of Calibre Scientific,” commented Managing Director of DCS, Christian Sartori. “We’ve developed extensive expertise in European diagnostics markets, and Calibre Scientific’s expansive portfolio and commercial infrastructure is the perfect fit to help take DCS to the next level.”
